ArticleThe Journal of clinical investigation2026
T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.
Lianghua Shen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.